ADC Therapeutics touts early Zynlonta results in marginal zone lymphoma, raises $105M through share sale

In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initiated study in marginal zone lymphoma (MZL).